Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$107.97 USD

107.97
2,246,218

+1.79 (1.69%)

Updated Apr 26, 2024 03:59 PM ET

After-Market: $107.85 -0.12 (-0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Can Biogen (BIIB) Keep the Beat Streak Alive in Q4 Earnings?

Biogen's (BIIB) sales in the fourth quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have risen.

Moderna (MRNA) Stock Slides as Market Rises: Facts to Know Before You Trade

In the most recent trading session, Moderna (MRNA) closed at $99.30, indicating a -0.73% shift from the previous trading day.

AstraZeneca (AZN) to Report Q4 Earnings: Here's What to Expect

Sales of AstraZeneca's (AZN) key drugs like Imfinzi and Farxiga are expected to have been boosted by approvals in new indications.

Gilead (GILD) Gears Up to Report Q4 Earnings: Whats in Store?

Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its fourth-quarter 2023 results.

Moderna (MRNA) Stock Moves -1.39%: What You Should Know

Moderna (MRNA) concluded the recent trading session at $101.05, signifying a -1.39% move from its prior day's close.

The Zacks Analyst Blog Highlights Oracle, Progressive, MercadoLibre, Moderna and Agilent

Oracle, Progressive, MercadoLibre, Moderna and Agilent are included in this Analyst Blog.

Sheraz Mian headshot

Top Stock Reports for Oracle, Progressive & MercadoLibre

Today's Research Daily features new research reports on 16 major stocks, including Oracle Corporation (ORCL), The Progressive Corporation (PGR) and MercadoLibre, Inc. (MELI).

Can Moderna's (MRNA) Launches Reduce COVID Sales Dependency?

With COVID-19 vaccine sales declining, Moderna (MRNA) is accelerating the development of its non-COVID pipeline. It is gearing up for potential product launches over the next five years.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Moderna (MRNA) Stock Declines While Market Improves: Some Information for Investors

In the latest trading session, Moderna (MRNA) closed at $101.11, marking a -0.79% move from the previous day.

Moderna (MRNA) Falls More Steeply Than Broader Market: What Investors Need to Know

Moderna (MRNA) closed at $100.35 in the latest trading session, marking a -1.77% move from the prior day.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Biotech Stock Roundup: REGN Down on Eylea Update, MRNA Gains on Preliminary Results

Preliminary Q4 and 2023 results from Regeneron (REGN) and Moderna (MRNA) were key highlights this week in the biotech sector.

Moderna (MRNA) Stock Drops Despite Market Gains: Important Facts to Note

The latest trading day saw Moderna (MRNA) settling at $109.46, representing a -0.65% change from its previous close.

Moderna (MRNA) Issues 2023 Preliminary Results, Stock Up 4%

Moderna (MRNA) reports unaudited product sales of around $6.7 billion for 2023, meeting its previously issued guidance. Share price rises following the announcement.

Moderna (MRNA) Ascends While Market Falls: Some Facts to Note

Moderna (MRNA) closed the most recent trading day at $108.66, moving +0.07% from the previous trading session.

Sanghamitra Saha headshot

Time to Buy Moderna-Heavy ETFs on Vaccine Optimism?

Shares of Moderna witnessed a significant increase of more than 13% on Jan 2, 2024, driven by Oppenheimer's decision to upgrade the stock to "outperform," as quoted on CNBC.

Why Moderna (MRNA) Stock Price Was Up 13% on Tuesday

Moderna (MRNA) surges after analysts at Oppenheimer upgraded its rating in anticipation of the company marketing five products by 2026.

Moderna (MRNA) Moves 13.1% Higher: Will This Strength Last?

Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Company News for Jan 3, 2024

Companies in The News Are: MRNA, RCL, NVDA, MRK

Why the Market Dipped But Moderna (MRNA) Gained Today

In the latest trading session, Moderna (MRNA) closed at $99.45, marking a +0.67% move from the previous day.

Stock Market News for Dec 28, 2023

Wall Street closed higher on Wednesday, with the S&P 500, the Dow and the Nasdaq notching their longest winning streak since 2017.

Biotech Stock Roundup: CGEN Up on GILD Deal, MRNA Gains on Study Data & More

Compugen (CGEN) and Moderna (MRNA) are in the news on collaboration and study updates, respectively.

FDA Expands Merck's (MRK) Welireg Label in Renal Cell Carcinoma

Per Merck (MRK), the latest FDA approval to Welireg marks the first time a new treatment has been approved in a novel therapeutic class in advanced renal cell carcinoma since 2015.

Moderna (MRNA) Soars on Upbeat Data From Cancer Therapy Study

Three-year follow up data from a mid-stage study shows that treatment with Moderna (MRNA)/Merck's cancer combination therapy reduces recurrence/death risk in certain melanoma patients by half.